Clinical trials: Small Cell Lung Cancer Recurrent
Small Cell Lung Cancer
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer…
- Trial name
- TRINITY (NCT02674568)
- Testing
- Rovalpituzumab tesirine
- Volunteers
- 342 people
- Sponsor
- AbbVie
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Small Cell Lung Cancer
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy…
- Trial name
- NCT06931626
- Testing
- NMS-03305293, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Nerviano Medical Sciences
Lung Cancer - Non Small Cell Squamous
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
- Trial name
- NCT01285609
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 290 sites in United States, Argentina and 34 more
- Volunteers
- 1,289 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell…
- Trial name
- CheckMate-1533 (NCT06946797)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 38 sites in United States, Brazil and 7 more
- Volunteers
- 76 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers.
- Conditions
- Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02729298
- Testing
- TP-0903
- Where
- 16 sites in United States
- Volunteers
- 177 people
- Sponsor
- Sumitomo Pharma America, Inc.
Lung Cancer, Non-small Cell Lung Cancer
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy…
- Trial name
- NCT03390686
- Testing
- Bevacizumab, HD204, Carboplatin
- Where
- 18 sites in Belarus, Bulgaria and 15 more
- Volunteers
- 650 people
- Sponsor
- Prestige Biopharma Limited
Small Cell Lung Cancer
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06612151
- Testing
- YL201, topotecan hydrochloride for injection
- Where
- China
- Volunteers
- 438 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than…
- Trial name
- NCT01160744
- Testing
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6)
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous…
- Trial name
- NCT01333007
- Where
- 152 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are…
- Trial name
- DISCOVER (NCT02029729)
- Testing
- omaveloxolone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Biogen
Lung Cancer
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with…
- Trial name
- NCT03348904
- Testing
- Nivolumab, Epacadostat, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Incyte Corporation
Small Cell Lung Cancer
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.
- Trial name
- NCT00472771
- Testing
- INNO-206
- Where
- 7 sites in United States
- Sponsor
- CytRx
Relapse, Advanced Malignant Neoplasm
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).
- Conditions
- Relapse, Advanced Malignant Neoplasm, Non Small Cell Lung Cancer, Gastric Cancer
- Trial name
- JIVAN (NCT05861947)
- Testing
- AUR106
- Where
- 6 sites in India
- Volunteers
- 21 people
- Sponsor
- Aurigene Discovery Technologies Limited
Non-small Cell Lung Cancer
Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
This active surveillance aims to collect the safety data of 100 NSCLC patients treated with nintedanib per the approved Indian label within 2 years from the date of commercial availability of the drug in India (23rd January…
- Trial name
- NCT03017885
- Where
- 11 sites in India
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to…
- Trial name
- NCT06405230
- Testing
- Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
- Trial name
- NCT06922539
- Testing
- Fenretinide
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- SciTech Development, Inc.
Non-small Cell Lung Cancer
Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT01597258
- Testing
- Crizotinib (Xalkori)
- Volunteers
- 2,029 people
- Sponsor
- Pfizer